* 中国生物科技公司--康宁杰瑞制药9966.HK周三早盘升5.1%。
* 该公司此前公告称，与石药集团1093.HK附属公司津曼特生物合作开发的安尼妥单抗联合注射用多西他赛（白蛋白结合型）用于人类表皮生长因子受体2阳性早期或局部晚期乳腺癌新辅助治疗的新药上市申请已获中国国家药监局受理，并纳入优先审评审批程序。
* 康宁杰瑞制药今年迄今跌18.9%，同期恒生指数.HSI上扬1%。
* 恒⽣⽣物科技指数.HSBIO盘中一度升2.1%。（完）
更多股市简讯请点选CN-CMN-HOT
* 中国生物科技公司--康宁杰瑞制药9966.HK周三早盘升5.1%。
* 该公司此前公告称，与石药集团1093.HK附属公司津曼特生物合作开发的安尼妥单抗联合注射用多西他赛（白蛋白结合型）用于人类表皮生长因子受体2阳性早期或局部晚期乳腺癌新辅助治疗的新药上市申请已获中国国家药监局受理，并纳入优先审评审批程序。
* 康宁杰瑞制药今年迄今跌18.9%，同期恒生指数.HSI上扬1%。
* 恒⽣⽣物科技指数.HSBIO盘中一度升2.1%。（完）
更多股市简讯请点选CN-CMN-HOT
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.